Comparative Pharmacology
Head-to-head clinical analysis: DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE versus EMERPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE versus EMERPHED.
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE vs EMERPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexbrompheniramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
EMERPHED is a combination of ephedrine and phenylephrine. Ephedrine is a sympathomimetic amine that acts directly on alpha and beta adrenergic receptors and indirectly by releasing norepinephrine from nerve endings, causing vasoconstriction, bronchodilation, and increased heart rate and blood pressure. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
1 tablet (each containing dexchlorpheniramine maleate 2 mg/pseudoephedrine sulfate 120 mg) orally every 12 hours; maximum 2 tablets per day.
Adults: 1-2 capsules (25-50 mg ephedrine sulfate) orally every 3-4 hours as needed, not to exceed 150 mg in 24 hours.
None Documented
None Documented
Dexbrompheniramine: terminal elimination half-life is approximately 12-25 hours in adults. Pseudophedrine: terminal elimination half-life is about 5-8 hours in adults with normal renal function; it is prolonged in patients with renal impairment.
Terminal elimination half-life: 3-6 hours (prolonged in renal impairment: up to 15 hours).
Dexbrompheniramine and its metabolites are primarily excreted renally (approximately 80-85% of a dose as unchanged drug and metabolites). Pseudophedrine is largely excreted unchanged in urine (70-90%) via glomerular filtration and tubular secretion; the remainder is hepatically metabolized. Biliary/fecal elimination is minimal (<5%).
Renal excretion of unchanged drug (~30-50%) and metabolites; minor biliary/fecal elimination (<10%).
Category A/B
Category C
Sympathomimetic
Sympathomimetic